Background
Patients and methods
Patients
Measurement of serum CXCL13 and CXCL13/CXCR5 immunohistochemistry
Statistics
Results
Characteristics of patients
PFS
|
OS
| ||||||
---|---|---|---|---|---|---|---|
Characteristics
|
n
|
%
|
HR
|
P
|
HR
|
P
| |
Age (years) | ≤60 | 56 | 81 | ||||
>60 | 13 | 19 | 2.164 | 0.039 | 2.489 | 0.024 | |
Sex | Male | 46 | 33 | ||||
Female | 23 | 67 | 1.215 | 0.575 | 0.752 | 0.494 | |
Performance status | ECOG 0/1 | 56 | 81 | ||||
ECOG ≥2 | 13 | 19 | 4.372 | <0.001 | 3.736 | 0.001 | |
Ann Arbor stage | I/II | 29/11 | 42/16 | ||||
III/IV | 5/24 | 7/35 | 1.935 | <0.001 | 1.898 | <0.001 | |
Serum LD | Normal | 30 | 44 | ||||
Increased | 39 | 56 | 3.124 | 0.002 | 2.456 | 0.026 | |
B symptoms | Absence | 39 | 56 | ||||
Presence | 30 | 44 | 2.634 | 0.004 | 2.310 | 0.027 | |
LN involvement | Absence | 40 | 58 | ||||
Presence | 29 | 42 | 2.236 | 0.017 | 3.258 | 0.002 | |
Primary site | Nasal | 41 | 59 | ||||
Extranasal | 28 | 41 | 4.092 | <0.001 | 4.240 | <0.001 | |
Bone marrow invasion | No | 56 | 81 | ||||
Yes | 13 | 19 | 6.591 | <0.001 | 5.298 | <0.001 | |
Extranodal involvement | 0/1 | 43 | 62 | ||||
≥2 | 26 | 38 | 2.948 | 0.001 | 2.616 | 0.011 | |
EBV DNA | Non-detectable | 42 | 61 | ||||
Detectable | 27 | 39 | 4.111 | <0.001 | 3.482 | <0.001 | |
IPI | Low/low-intermediate | 33/11 | 48/16 | ||||
High-intermediate/High | 17/8 | 24/12 | 2.482 | <0.001 | 2.031 | <0.001 | |
NKPI | Group I/II | 18/8 | 26/12 | ||||
Group III/IV | 20/23 | 29/33 | 2.162 | <0.001 | 2.036 | 0.001 | |
GPS | 0 | 32 | 46 | ||||
1 | 22 | 32 | |||||
2 | 15 | 22 | 2.660 | <0.001 | 3.052 | <0.001 |
Serum CXCL13 and the GPS
CXCL13
|
GPS
| ||||||
---|---|---|---|---|---|---|---|
Characteristics
|
Low
|
High
|
P
|
0/1
|
2
|
P
| |
Age (years) | ≤60 | 32 | 24 | 48 | 8 | ||
>60 | 3 | 10 | 0.034 | 6 | 7 | 0.005 | |
Ann Arbor stage | I/II | 30 | 10 | 37 | 3 | ||
III/IV | 5 | 24 | <0.001 | 17 | 12 | 0.001 | |
Serum LDH | Normal | 22 | 8 | 28 | 2 | ||
Increased | 13 | 26 | 0.001 | 26 | 13 | 0.009 | |
B symptoms | Absence | 25 | 14 | 35 | 4 | ||
Presence | 10 | 20 | 0.015 | 19 | 11 | 0.017 | |
LN involvement | Absence | 25 | 15 | 36 | 4 | ||
Presence | 10 | 19 | 0.029 | 18 | 11 | 0.008 | |
Primary site | Nasal | 29 | 12 | 38 | 3 | ||
Extranasal | 6 | 22 | <0.001 | 16 | 12 | 0.001 | |
Bone marrow invasion | No | 33 | 23 | 49 | 7 | ||
Yes | 2 | 11 | 0.006 | 5 | 8 | 0.001 | |
Extranodal involvement | 0/1 | 29 | 14 | 38 | 5 | ||
≥2 | 6 | 20 | <0.001 | 16 | 10 | 0.015 | |
EBV DNA | Non-detectable | 29 | 13 | 38 | 4 | ||
Detectable | 6 | 21 | <0.001 | 16 | 11 | 0.006 | |
IPI | L/LI | 30 | 14 | 42 | 2 | ||
HI/H | 5 | 20 | <0.001 | 12 | 13 | <0.001 | |
NKPI | Group I/II | 22 | 4 | 24 | 2 | ||
Group III/IV | 13 | 30 | <0.001 | 30 | 13 | 0.036 |